Literature DB >> 31241411

The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.

Olusegun O Onabajo1, Brian Muchmore1, Ludmila Prokunina-Olsson1.   

Abstract

Since its discovery in 2013, interferon lambda 4 (IFN-λ4) has received a reputation as a paradoxical type III IFN. Difficulties in detecting IFN-λ4, especially in secreted form even led to questions about its existence. However, the genetic ability to generate IFN-λ4, determined by the presence of the rs368234815-ΔG allele, is the strongest predictor of impaired clearance of hepatitis C virus (HCV) infection in humans. Significant modulation of IFN-λ4 activity by a genetic variant (P70S) supports IFN-λ4, and not other type III IFNs encoded in the same genomic locus, as the primary functional cause of the association with HCV clearance. Although the ability to produce IFN-λ4 is associated with decreased HCV clearance, the recombinant IFN-λ4 is active against HCV and other viruses. These observations present an apparent conundrum-when and how does a presumably good IFN, with anti-HCV activity, interfere with the ability to clear HCV? In this review, we discuss findings that suggest potential mechanisms for explaining this conundrum.

Entities:  

Keywords:  HCV; IFN-λ4; SOCS1; USP18; regulation; type III interferon

Mesh:

Substances:

Year:  2019        PMID: 31241411      PMCID: PMC6767864          DOI: 10.1089/jir.2019.0044

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  40 in total

1.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

2.  Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype.

Authors:  Aryn A Price; Dana Tedesco; Mona R Prasad; Kimberly A Workowski; Christopher M Walker; Mehul S Suthar; Jonathan R Honegger; Arash Grakoui
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

3.  IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18.

Authors:  Weiguo Fan; Shiqi Xie; Xinhao Zhao; Nan Li; Chong Chang; Li Li; Ge Yu; Xiumei Chi; Yu Pan; Junqi Niu; Jin Zhong; Bing Sun
Journal:  J Gen Virol       Date:  2016-06-14       Impact factor: 3.891

4.  High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism.

Authors:  Alessandro Antonelli; Mario Rotondi; Poupak Fallahi; Paola Romagnani; Silvia Martina Ferrari; Andrea Buonamano; Ele Ferrannini; Mario Serio
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

5.  Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.

Authors:  Kyung-Ah Kim; Wenyu Lin; Andrew W Tai; Run-Xuan Shao; Ethan Weinberg; Carolina B De Sa Borges; Atul K Bhan; Hui Zheng; Yoshitaka Kamegaya; Raymond T Chung
Journal:  J Hepatol       Date:  2009-02-14       Impact factor: 25.083

6.  HCV infection selectively impairs type I but not type III IFN signaling.

Authors:  Partha K Chandra; Lili Bao; Kyoungsub Song; Fatma M Aboulnasr; Darren P Baker; Nathan Shores; William C Wimley; Shuanghu Liu; Curt H Hagedorn; Serge Y Fuchs; Tong Wu; Luis A Balart; Srikanta Dash
Journal:  Am J Pathol       Date:  2013-11-09       Impact factor: 4.307

7.  HCV replication in PBMC and its influence on interferon therapy.

Authors:  Guo-Zhong Gong; Li-Ying Lai; Yong-Fang Jiang; Yan He; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

8.  Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family.

Authors:  Hans Henrik Gad; Christoffer Dellgren; Ole J Hamming; Susanne Vends; Søren R Paludan; Rune Hartmann
Journal:  J Biol Chem       Date:  2009-05-20       Impact factor: 5.157

9.  Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.

Authors:  Marcello Persico; Mario Capasso; Eliana Persico; Monica Svelto; Roberta Russo; Daniela Spano; Lori Crocè; Vincenzo La Mura; Francesco Moschella; Flora Masutti; Roberto Torella; Claudio Tiribelli; Achille Iolascon
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

10.  HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations.

Authors:  Lorenzo Uccellini; Fan-Chen Tseng; Alessandro Monaco; Fatma M Shebl; Ruth Pfeiffer; Myhanh Dotrang; Dianna Buckett; Michael P Busch; Ena Wang; Brian R Edlin; Francesco M Marincola; Thomas R O'Brien
Journal:  Hepatology       Date:  2012-06-01       Impact factor: 17.425

View more
  11 in total

1.  Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers.

Authors:  Frank J Jenkins; Tsion Z Minas; Wei Tang; Tiffany H Dorsey; Stefan Ambs
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-04-25       Impact factor: 5.554

Review 2.  Herpesviruses and the Type III Interferon System.

Authors:  Yue Yin; Herman W Favoreel
Journal:  Virol Sin       Date:  2021-01-05       Impact factor: 4.327

3.  IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections.

Authors:  Belson Rugwizangoga; Maria E Andersson; Jean-Claude Kabayiza; Malin S Nilsson; Brynja Ármannsdóttir; Johan Aurelius; Staffan Nilsson; Kristoffer Hellstrand; Magnus Lindh; Anna Martner
Journal:  Front Cell Infect Microbiol       Date:  2019-10-04       Impact factor: 5.293

4.  IFN-λ4 genetic variants influence clinical malaria episodes in a cohort of Kenyan children.

Authors:  Gabriela Samayoa-Reyes; Conner Jackson; Sidney Ogolla; Katherine Sabourin; Adeola Obajemu; Arlene E Dent; Ludmilla Prokunina-Olsson; Rosemary Rochford
Journal:  Malar J       Date:  2021-04-21       Impact factor: 2.979

5.  IFN-λ4 is associated with increased risk and earlier occurrence of several common infections in African children.

Authors:  Ludmila Prokunina-Olsson; Robert D Morrison; Adeola Obajemu; Almahamoudou Mahamar; Sungduk Kim; Oumar Attaher; Oscar Florez-Vargas; Youssoufa Sidibe; Olusegun O Onabajo; Amy A Hutchinson; Michelle Manning; Jennifer Kwan; Nathan Brand; Alassane Dicko; Michal Fried; Paul S Albert; Sam M Mbulaiteye; Patrick E Duffy
Journal:  Genes Immun       Date:  2021-04-13       Impact factor: 2.676

Review 6.  Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.

Authors:  Megan L Stanifer; Cuncai Guo; Patricio Doldan; Steeve Boulant
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

7.  Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study.

Authors:  Shahinaz M Gadalla; Youjin Wang; Tao Wang; Olusegun O Onabajo; A Rouf Banday; Adeola Obajemu; Ezgi Karaesman; Lara Sucheston-Campbell; Theresa Hahn; Jennifer A Sees; Stephen R Spellman; Stephanie J Lee; Hormuzd A Katki; Ludmila Prokunina-Olsson
Journal:  Lancet Haematol       Date:  2020-10       Impact factor: 18.959

8.  Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion.

Authors:  Achille Broggi; Francesca Granucci; Ivan Zanoni
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

9.  Distinct molecular phenotypes involving several human diseases are induced by IFN-λ3 and IFN-λ4 in monocyte-derived macrophages.

Authors:  Manjarika De; Anand Bhushan; William S Grubbe; Subhajit Roy; Juan L Mendoza; Sreedhar Chinnaswamy
Journal:  Genes Immun       Date:  2022-02-03       Impact factor: 4.248

10.  Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN-λ3 or IFN-λ4 show distinct phenotypes.

Authors:  Manjarika De; Anand Bhushan; Sreedhar Chinnaswamy
Journal:  J Leukoc Biol       Date:  2020-11-17       Impact factor: 6.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.